Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Invivyd, Inc.NASDAQ: IVVD

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $13.74M rose 21.6% year over year, behind the +52.3% change in trailing-twelve-month revenue. Sequentially, it fell 20.1% from the prior quarter.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 2 analysts of $60.33M (+12.9%) for the fiscal year ending Dec 2026, a slowdown from the +110.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.74M-20.1% QoQ
Last fiscal yearDec 2025
$53.43M+110.5% YoY
LTMMar 2026
$55.87M+52.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.6%+22.2%+0.6 pp
1 year+110.5%+12.9%-97.5 pp
3-year CAGR—+62.7%—
5-year CAGR+71.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
53.43M USD
Year-over-year change
+110.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's LTM Mar 2026 revenue of $55.87M is the 2nd highest of the 10 companies compared; the peer median is $28.91M.
  • Its year-over-year change of +52.3% is the 3rd highest of 7, against a peer median of -2.1%.
IVVD Competitors Peer median
Revenue for IVVD and competitors
Company Period LTM YoY 3-year CAGR
CDXSCodexis, Inc.LTM Mar 2026$78.09M +56.8%-20.2%
IVVDInvivyd, Inc.LTM Mar 2026$55.87M +52.3%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.86M -12.4%+5.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M -45.8%-29.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.72M +1033.9%+111.6%
OABIOmniAb, Inc.LTM Mar 2026$28.91M +8.1%-31.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$1.95M -49.3%+61.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ——
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 ——
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$0 ——
Peer median (excluding IVVD) $28.91M-2.1%-7.6%

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00025.38M53.43M
Cost of Revenue0001.62M3.75M
Gross Profit00023.77M49.68M
Gross Margin———93.6%93.0%
Research & Development182.89M179.21M158.66M137.25M38.31M
Selling, General & Admin36.52M47.04M49.13M63.39M66.93M
Operating Expenses226.91M248.03M212.76M200.64M105.24M
Depreciation & Amortization1K462K2.03M3.11M2.11M
EBITDA(219.41M)(225.8M)(205.76M)(166.81M)(50.38M)
EBITDA Margin———-657.2%-94.3%
Operating Income(226.91M)(248.03M)(212.76M)(176.88M)(55.56M)
Operating Margin———-696.8%-104.0%
Interest Income06.71M06.95M0
Interest Expense043.08M000
Other Income / Expenses118K6.71M14.12M6.95M3.07M
Income Before Tax(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Pre-Tax Margin———-669.4%-98.2%
Income Tax Expense00000
Net Income(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Net Margin———-669.4%-98.2%
EPS (Basic)(2.11)(2.17)(1.81)(1.43)(0.30)
EPS (Diluted)(2.11)(2.17)(1.81)(1.43)(0.30)
Weighted Avg Shares110.78M108.27M109.53M118.56M172.21M
Weighted Avg Shares (Diluted)110.78M108.27M109.53M118.56M172.21M

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.